Agios Pharmaceuticals

Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases. Metabolism is a complex biological process involving the uptake and assimilation of nutrients in cells to produce energy and facilitate many of the processes required for cellular division and growth. We believe that dysregulation of normal cellular metabolism plays a crucial role in many diseases, including certain cancers and rare diseases Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. We intend to apply our deep understanding of metabolism, coupled with our ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.
Company Growth (employees)
Cambridge, US
Size (employees)
287 (est)+38%
Agios Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
88 Sidney St

Agios Pharmaceuticals Data and Metrics

Agios Pharmaceuticals Financial Metrics

Agios Pharmaceuticals's revenue was reported to be $69.9 m in 2016
$, USD

Revenue (Y, 2016)

69.9 m

Revenue growth (Y, 2015 - Y, 2016), %


Net income (Y, 2016)

(198.5 m)

EBIT (Y, 2016)

(201 m)

Market capitalization (23-Jun-2017)

2.9 b

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

160.8 m
Agios Pharmaceuticals's current market capitalization is $2.9 b.
$, USDFY, 2013FY, 2014FY, 2015Y, 2016


25.5 m65.4 m59.1 m69.9 m

Revenue growth, %


Operating expense total

64.4 m119.5 m177.8 m270.9 m


(38.9 m)(54.1 m)(118.7 m)(201 m)

EBIT margin, %


Interest income

55 k203 k968 k2.5 m

Pre tax profit

(117.7 m)(198.5 m)

Income tax expense

579 k(426 k)(426 k)

Net Income

(39.4 m)(53.5 m)(117.7 m)(198.5 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


71.6 m14 m71.8 m160.8 m

Accounts Receivable

2.3 m


2.5 m4.8 m8.7 m10.3 m

Current Assets

169.7 m359.5 m337.3 m559.9 m


3.8 m6.4 m23.2 m25.3 m

Total Assets

201.2 m491.9 m420.1 m619.1 m

Accounts Payable

3.7 m11.1 m14.7 m17.1 m

Current Liabilities

36.9 m61.1 m52.9 m88.4 m

Additional Paid-in Capital

244.9 m591.3 m630.1 m842 m

Retained Earnings

(113.4 m)(166.9 m)(284.7 m)(483.2 m)

Total Equity

131.5 m424.4 m345.1 m358.6 m

Financial Leverage

1.5 x1.2 x1.2 x1.7 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(39.4 m)(53.5 m)(117.7 m)(198.5 m)

Depreciation and Amortization

1.4 m1.4 m3.3 m5.7 m

Accounts Receivable

(2.3 m)(1 m)

Accounts Payable

30 k7.6 m4.2 m3.5 m

Cash From Operating Activities

(56.4 m)(59.4 m)(76.9 m)38.6 m

Purchases of PP&E

(1.3 m)(2.2 m)(20.2 m)(9.9 m)

Cash From Investing Activities

(87.2 m)(333.3 m)128.3 m(119.4 m)

Cash From Financing Activities

123.9 m335.2 m6.4 m169.8 m

Income Taxes Paid

6 m6 m6 m
Y, 2016

Financial Leverage

1.7 x

Agios Pharmaceuticals Market Value History

Agios Pharmaceuticals Job Categories

Agios Pharmaceuticals News and Updates

Agios Pharmaceuticals Company Life and Culture

You may also be interested in